Arcturus Therapeutics Financials - Benzinga

Arcturus Therapeutics Holdings Inc

ARCTNASDAQ

Trade with Public

Trade with Public

$14.73

0.755.36%

At close: Sep 11, 5:00 PM EST

$14.73

N/A

After Hours: Sep 11, 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Arcturus Therapeutics Financials

Arcturus Therapeutics (ARCT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Arcturus Therapeutics Q2 EPS $(0.84) Beats $(1.00) Estimate, Sales $2.959M Miss $3.199M Estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.00) by 16 percent. This is a 147.06 percent decrease over losses of $(0.34) per share

Benzinga Newsdesk

PRO
Arcturus Therapeutics Q1 EPS $(0.95) Beats $(1.00) Estimate, Sales $2.061M Miss $7.233M Estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.00) by 5 percent. This is a 82.69 percent decrease over losses of $(0.52) per share from

Benzinga Newsdesk

Arcturus Therapeutics Q4 Earnings Assessment

Benzinga Insights

PRO
Arcturus Therapeutics Q4 EPS $(1.03) Misses $(0.98) Estimate, Sales $7.196M Miss $17.669M Estimate

Benzinga Newsdesk

Earnings Scheduled For March 3, 2026

Benzinga Insights

Earnings Preview: Arcturus Therapeutics

Benzinga Insights